Clinical Trial Update: Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. [Phase 2]

View source ↗

Summary

Phase II trial evaluating olaparib in combination with abiraterone for metastatic castration-resistant prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-10-02